Clinical Trials Browser

Phase 2/3 × Recruiting × Bevacizumab × Clear all

NCT07221357 2026-03-17

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT07293468 2025-12-19

BIIRTH

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06109272 2025-08-15

LIVIGNO-2

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06280495 2025-05-30

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05462613 2024-12-20

REPROGRAM-02

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms